Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Arena Pharmaceuticals (ARNA) -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (1423)	8/20/2009 10:48:41 AM
From: tuck	Respond to of 2274

A general look at the state of the GPCR landscape over the last few years, and how much it has changed: pipeline.corante.com Cheers, Tuck

To: mopgcw who wrote (1423)	3/12/2010 8:15:27 AM
From: scaram(o)uche	Respond to of 2274

16 months ago....... Message 25255721 >> Ortho-McNeil's Phase 1 program will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of APD597 in single and multiple ascending dose studies in healthy volunteers << today's release...... Ortho-McNeil-Janssen Pharmaceuticals, Inc., or Ortho-McNeil-Janssen, completed a Phase 1 clinical trial in healthy volunteers evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of APD597, a novel oral drug candidate that targets GPR119 for the treatment of type 2 diabetes. Ortho-McNeil-Janssen has initiated another clinical trial evaluating multiple ascending doses of APD597. Nothing new, just a desperate attempt to pad an empty presentation. No phase II. Thank you, Lief.